Legal & General Group Plc lifted its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 75.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,245 shares of the company’s stock after buying an additional 5,711 shares during the period. Legal & General Group Plc’s holdings in Aerie Pharmaceuticals were worth $644,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Aerie Pharmaceuticals by 55.0% during the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after purchasing an additional 766,300 shares during the period. Senzar Asset Management LLC bought a new position in Aerie Pharmaceuticals during the second quarter worth about $20,568,000. Broadfin Capital LLC bought a new position in Aerie Pharmaceuticals during the second quarter worth about $16,291,000. AXA bought a new position in Aerie Pharmaceuticals during the second quarter worth about $10,961,000. Finally, Bank of New York Mellon Corp lifted its stake in Aerie Pharmaceuticals by 64.8% during the second quarter. Bank of New York Mellon Corp now owns 436,955 shares of the company’s stock worth $22,962,000 after purchasing an additional 171,879 shares during the period.
Aerie Pharmaceuticals Inc (NASDAQ AERI) opened at $60.60 on Friday. Aerie Pharmaceuticals Inc has a one year low of $37.80 and a one year high of $66.60. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. The stock has a market cap of $2,222.47, a P/E ratio of -18.14 and a beta of 1.11.
ILLEGAL ACTIVITY WARNING: “Legal & General Group Plc Grows Position in Aerie Pharmaceuticals Inc (AERI)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3126493/legal-general-group-plc-grows-position-in-aerie-pharmaceuticals-inc-aeri.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.